Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke

Basit Öğe Kaydı
dc.contributor.authorIltumur, Kenan
dc.contributor.authorKarabulut, Aziz
dc.contributor.authorApak, Ismail
dc.contributor.authorAluclu, Ufuk
dc.contributor.authorAriturk, Zuhal
dc.contributor.authorToprak, Nizamettin
dc.date.accessioned2024-04-24T16:10:43Z
dc.date.available2024-04-24T16:10:43Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground B-type natriuretic peptide (BNP) is a neurohormone secreted mainly in the cardiac ventricles in response to volume expansion and pressure overload. The aim of this study was to assess plasma N-terminal proBNP (NT-proBNP) changes in acute ischemic stroke (AIS). Methods The study group consisted of 57 (37 women aged 64 12 years) patients who had their first AIS and no history or signs of cardiovascular disease. An age-matched control group was also included (n = 57, 36 women aged 61 6 years). NT-proBNP, troponin I (TnI), and creatine kinase-MB were evaluated. A thorough cardiovascular and neurological investigation, including imaging techniques and lesion size determination, was also performed. Results The log NT-proBNP peak levels, TnI, and creatine kinase-MB levels were significantly higher in AIS compared with controls (7.25 +/- 1.77 vs 3.48 +/- 0.76 mu g/mL, P < .0001; 0.76 +/- 0.54 vs 0.5 +/- 0.0 ng/mL, P < .001; 57 +/- 37 vs 13 +/- 4 U/L, P < .001, respectively). The log NT-proBNP correlated positively with TnI (r = 0.29, P = .03) and heart rate (r = 0.41, P = .002), and negatively with left ventricular ejection fraction (r = -0.67, P < .0001). Patients with signs of marked myocardial ischemia and patients with insular cortex involvement had even higher NT-proBNP levels. After adjustment for relevant factors, the relation between the log NT-proBNP and AIS as well as insular cortex involvement was observed to be insignificant (P > .05 for both). Conclusions Our results show that NT-proBNP plasma levels are significantly elevated in AIS and might be of clinical importance as a supplementary tool for the assessment of cardiovascular function in patients with AIS.en_US
dc.identifier.doi10.1016/j.ahj.2005.05.022
dc.identifier.endpage1122en_US
dc.identifier.issn0002-8703
dc.identifier.issn1097-5330
dc.identifier.issue5en_US
dc.identifier.pmid16644347
dc.identifier.scopus2-s2.0-33646110735
dc.identifier.scopusqualityQ1
dc.identifier.startpage1115en_US
dc.identifier.urihttps://doi.org/10.1016/j.ahj.2005.05.022
dc.identifier.urihttps://hdl.handle.net/11468/15063
dc.identifier.volume151en_US
dc.identifier.wosWOS:000237638200038
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherMosby-Elsevieren_US
dc.relation.ispartofAmerican Heart Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleElevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic strokeen_US
dc.titleElevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu